Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.

Oncoimmunology · 2020 · PMC7595592 · PMID 33178494

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Changes in plasma levels are showed also for sBTN3A1 and sBTN3 global, but these difference T0-T1 did not reach statistical significance ( Figure 4(a–d) ). 3.4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.